Logo

NeoGenomics: David Eberhard

Dec 13, 2021

NeoGenomics has appointed David Eberhard as chief medical officer of Inivata, NeoGenomics' liquid biopsy-focused subsidiary. Eberhard will be in charge of the clinical and strategic development of the subsidiary's liquid biopsy tests, including the RaDaR test for minimal residual disease. He most recently served as senior medical director of oncology at Illumina and was previously the senior director of oncology development at Genomic Health, focusing on bringing the firm's OncotypeSEQ liquid biopsy test to market.

Breaking News
The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.